Titan Medical to Report Year-End 2020 Financial Results and Host Webcast on February 22, 2021
February 09 2021 - 10:21AM
Business Wire
Titan Medical Inc. (“Titan” or the “Company”)
(TSX: TMD) (Nasdaq: TMDI), a medical
device company focused on the design and development of surgical
technologies for robotic single access surgery, announces that the
Company plans to issue its fourth quarter and year-end financial
results prior to market opening Monday, February 22, 2021 and
management will host an investor audio webcast at 4:30 pm ET to
discuss financial results and business highlights. Speakers will
include David J. McNally, President and Chief Executive Officer,
Monique L. Delorme, Chief Financial Officer, and Perry A. Genova,
Ph.D., Senior Vice President, Research and Development.
A link to the live audio webcast will be made available on the
"Investor Relations" section of the Company’s website,
www.titanmedicalinc.com. A webcast replay will be archived and
accessible on the Company’s website shortly after conclusion of the
live audio webcast.
About Titan Medical
Titan Medical Inc., a medical device company headquartered in
Toronto, is focused on developing robotic assisted technologies for
application in single access surgery. The Enos™ system, by Titan
Medical, is being developed with dual 3D and 2D high-definition
vision systems, multi-articulating instruments, and an ergonomic
surgeon workstation. With the Enos system, Titan intends to
initially pursue gynecologic surgical indications.
Certain of Titan’s robotic assisted surgical technologies and
related intellectual property have been licensed to Medtronic plc,
while retaining world-wide rights to commercialize the technologies
for use with the Enos system.
Enos™ is a trademark of Titan Medical Inc.
For more information, please visit www.titanmedicalinc.com.
Forward-Looking Statements
This news release contains “forward-looking statements” within
the meaning of applicable Canadian and U.S. securities laws. Such
statements reflect the current expectations of management of the
Company’s future growth, results of operations, performance and
business prospects and opportunities. Wherever possible, words such
as “may”, “would”, “could”, “will”, “anticipate”, “believe”,
“plan”, “expect”, “intend”, “estimate”, “potential for” and similar
expressions have been used to identify these forward-looking
statements, including, without limitation, references to: the
Company’s focus on the design and development of surgical
technologies for robotic single access surgery, that the Enos
system is being developed with dual 3D and 2D high-definition
vision systems, multi-articulating instruments and an ergonomic
surgeon workstation and that Titan intends to initially pursue
gynecologic surgical indications. These statements reflect
management’s current beliefs with respect to future events and are
based on information currently available to management.
Forward-looking statements involve significant risks, uncertainties
and assumptions. Many factors could cause the Company’s actual
results, performance or achievements to be materially different
from any future results, performance or achievements that may be
expressed or implied by such forward-looking statements, including,
without limitation, those listed in the “Risk Factors” section of
the Company’s Annual Report on Form 20-F for the fiscal year ended
December 31, 2019 (which may be viewed at www.sedar.com and at
www.sec.gov). Should one or more of these risks or uncertainties
materialize, or should assumptions underlying the forward-looking
statements prove incorrect, actual results, performance, or
achievements may vary materially from those expressed or implied by
the forward-looking statements contained in this news release.
These factors should be considered carefully, and prospective
investors should not place undue reliance on the forward-looking
statements. Although the forward-looking statements contained in
the news release are based upon what management currently believes
to be reasonable assumptions, the Company cannot assure prospective
investors that actual results, performance or achievements will be
consistent with these forward-looking statements. Except as
required by law, the Company expressly disclaims any intention or
obligation to update or revise any forward-looking statements
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210209005839/en/
Monique L. Delorme Chief Financial Officer +1-416-548-7522
investors@titanmedicalinc.com
Titan Medical (TSX:TMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Titan Medical (TSX:TMD)
Historical Stock Chart
From Apr 2023 to Apr 2024